PNC Financial Services Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
VPM
VCM
DTC
PNC Financial Services Group's AXSM Position: Q1 2026 in Review
PNC Financial Services Group increased its Axsome Therapeutics (AXSM) stake by 8.3% in Q1 2026, buying an estimated $27.5K and bringing the position to 2,080 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #1939.
PNC Financial Services Group first reported a position in AXSM in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.71M in Q2 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- PNC Financial Services Group held 2,080 shares of Axsome Therapeutics worth $352K as of Q1 2026.
- PNC Financial Services Group bought 159 Axsome Therapeutics shares in Q1 2026, an estimated $27.5K.
- Axsome Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #1939 holding.
- PNC Financial Services Group first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 26 quarters since.
- PNC Financial Services Group's Axsome Therapeutics position peaked at $1.71M in Q2 2020.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.